Pharming Group stock
PHARM.ASAMSPharming Group N.V., HealthcareISIN NL0010391025
49Score 49 out of 100, Weak
Price and trend
56 / 100
Price history
−20% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 0.2% above it.
Since May 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 77).
The price is 35% below its 52-week high. Largest decline in 20 years: 100% (October 2007 to April 2013).
Chart figures for advanced users
- SMA 50$1.07
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$1.29
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)77
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$0.92
- The lowest closing price of the last twelve months.
- Resistance$1.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Pharming Group N.V. belongs to the Biotechnology industry (Netherlands) and, with a market value of $914.74M, is number 196 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 49 out of 100 (Weak): rank 396 of 714 in Healthcare, median 53.
- The P/E is 39.6 (Biotechnology median 21.3, own median of recent years 30.1).
Show more
- Our model puts fair value at $0.56, with the price 137% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Share buybacksShare count down 15% since 2020.
- More cash than debtCash $186.42M, financial debt $112.61M.Stability 58
- Earnings turn into cashFree cash flow 126% of earnings over the last 12 months.Fundamentals 60
Weaknesses
- Earnings per share fallingDown 38.4% a year since 2020.Growth 36
- Above fair valuePrice 137% above the fair value of $0.56.Valuation 25
- Richly valuedP/E 39.6, Biotechnology median 21.3, own median 30.1.Valuation 25
The score is held back by capital allocation and valuation.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 48 to 49.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- price far below its 52-week high
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $0.40 and expensive above $0.93 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $0.42 (cash-flow model) and $0.69 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9.4%. At 10.4% the fair value would be $0.53, at 8.4% it would be $0.60.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 6.9% on the twelve months before. Revenue has grown strongly since 2006, at around 51% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 88%, operating 6%, net 1%. Last 12 months: net 6%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Mar 2027in 126 days
- Last reported
- 27 Oct 2026EPS reported 0.03 (expected 0.02)above expectations
Analyst estimates
- Earnings per share
- 0.03+26.6%
- Revenue
- $380.85M+0.4%
- Earnings per share
- 0.03+38.0%
- Revenue
- $395.45M+0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −20.1%2026 revenue guidance lowered by $30 million to $375 million to $395 million, operating expense guidance also reduced by $15 million.
“We have revised our 2026 revenue guidance to $375 million-$395 million, a reduction of $30 million from our previous outlook, reflecting the RUCONEST stabilization and return to growth and strong Joenja growth as discussed earlier.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Pharming Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 49
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- ImmaticsIMTX $1B29
- Climb BioCLYM $980.38M45
- PhilogenPHIL.MI $934.29M68
- Silence TherapeuticsSLN $933.82M44
- ORIC PharmaceuticalsORIC $932.87M32
- MeiraGTx HoldingsMGTX $929.7M61
- Aktis OncologyAKTS $915.84M37
- 4D Molecular TherapeuticsFDMT $912.83M48
ETFs that hold Pharming Group
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.16% | 0.40% | €575.19M |
| UBS MSCI EMU Small Cap UCITS ETF EUR disUEFD | 0.15% | 0.28% | €627.81M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.08% | 0.40% | €1.49B |
Show 5 more
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.08% | 0.23% | €319.31M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.04% | 0.30% | €3.43B |
| UBS MSCI EMU Select Factor Mix UCITS ETF EUR accUIQN | 0.02% | 0.34% | €16.87M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.02% | 0.30% | €810.11M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Overvalued since 10 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.